SUPPLEMENT

Q4 2022 — Financial disclosures

Q4 2022PDF · 10 pages1.0 MB
Merck & Co., Inc.
Financial Highlights Package
Fourth Quarter 2022
Table of Contents
Table 1: GAAP P&L.....................................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter..................2
Table 2a: GAAP to Non-GAAP Reconciliation 4Q22 and Dec YTD 22.........3
Table 2b: GAAP to Non-GAAP Reconciliation 4Q21 and Dec YTD 21.........4
Table 3: Sales - Current Year and Prior Year by Quarter...........................5
Table 3a: Sales – U.S. / Ex- U.S. 4Q22........................................................6
Table 3b: Sales – U.S. / Ex- U.S. Dec YTD 22............................................7
Table 3c: Sales – Pharmaceutical Geographic Split....................................8
Table 4: Other (Income) Expense .............................................................9

-- 1 of 10 --

Sales 	13,830	$ 	13,521	$ 	2% 	59,283	$ 	48,704	$ 	22%
Costs, Expenses and Other
Cost of sales 	3,881 	3,873 	0% 	17,411 	13,626 	28%
Selling, general and administrative 	2,687 	2,830 	-5% 	10,042 	9,634 	4%
Research and development 	3,775 	3,068 	23% 	13,548 	12,245 	11%
Restructuring costs 	49 	174 	-72% 	337 	661 	-49%
Other (income) expense, net 	(75) 	(333) 	-77% 	1,501 	(1,341) 	*
Income from Continuing Operations Before Taxes 	3,513 	3,909 	-10% 	16,444 	13,879 	18%
Income Tax Provision 	495 	85 	1,918 	1,521
Net Income from Continuing Operations 	3,018 	3,824 	-21% 	14,526 	12,358 	18%
Less: Net Income Attributable to Noncontrolling Interests 	1 	4 	7 	13
Net Income from Continuing Operations Attributable to Merck & Co., Inc. 	3,017 	3,820 	-21% 	14,519 	12,345 	18%
(Loss) Income from Discontinued Operations, Net of Taxes and
Amounts Attributable to Noncontrolling Interests - 	(62) 	* 	- 	704 	*
Net Income Attributable to Merck & Co., Inc. 	3,017	$ 	3,758	$ 	-20% 	14,519	$ 	13,049	$ 	11%
Basic Earnings (Loss) per Common Share Attributable to Merck & Co.,
Inc. Common Shareholders:
Income from Continuing Operations 	1.19	$ 	1.51	$ 	-21% 	5.73	$ 	4.88	$ 	17%
(Loss) Income from Discontinued Operations 	- 	(0.02) 	* 	- 	0.28 	*
Net Income 	1.19	$ 	1.49	$ 	-20% 	5.73	$ 	5.16	$ 	11%
Earnings (Loss) per Common Share Assuming Dilution Attributable to
Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations 	1.18	$ 	1.51	$ 	-22% 	5.71	$ 	4.86	$ 	17%
(Loss) Income from Discontinued Operations 	- 	(0.02) 	* 	- 	0.28 	*
Net Income 	1.18	$ 	1.48	$ 	-20% 	5.71	$ 	5.14	$ 	11%
Average Shares Outstanding 	2,536 	2,527 	2,532 	2,530
Average Shares Outstanding Assuming Dilution 	2,548 	2,535 	2,542 	2,538
Tax Rate from Continuing Operations 	14.1% 	2.2% 	11.7% 	11.0%
* 100% or greater
Full Year
2021
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
On June 2, 2021, Merck completed the spinoff of products from its women’s health, biosimilars and established brands businesses into a new,
independent, publicly traded company named Organon & Co. (Organon). The historical results of the businesses that were contributed to Organon in the
spin-off are excluded from sales and expenses below and reflected as discontinued operations in the company’s Consolidated Statements of Income
provided below.
4Q21
GAAP
% Change
GAAP
% Change
4Q22 Full Year
2022
1

-- 2 of 10 --

Sales 	15,901	$ 	14,593	$ 	14,959	$ 	13,830	$ 	59,283	$ 	10,627	$ 	11,402	$ 	13,154	$ 	13,521	$ 	48,704	$ 	2% 	22%
Costs, Expenses and Other
Cost of sales 	5,380 	4,216 	3,934 	3,881 	17,411 	3,199 	3,104 	3,450 	3,873 	13,626 	0% 	28%
Selling, general and administrative 	2,323 	2,512 	2,520 	2,687 	10,042 	2,187 	2,281 	2,336 	2,830 	9,634 	-5% 	4%
Research and development 	2,576 	2,798 	4,399 	3,775 	13,548 	2,412 	4,321 	2,445 	3,068 	12,245 	23% 	11%
Restructuring costs 	53 	142 	94 	49 	337 	297 	82 	107 	174 	661 	-72% 	-49%
Other (income) expense, net 	708 	438 	429 	(75) 	1,501 	(455) 	(103) 	(450) 	(333) 	(1,341) 	-77% 	*
Income from Continuing Operations Before Taxes 	4,861 	4,487 	3,583 	3,513 	16,444 	2,987 	1,717 	5,266 	3,909 	13,879 	-10% 	18%
Income Tax Provision 	554 	538 	330 	495 	1,918 	238 	503 	695 	85 	1,521
Net Income from Continuing Operations 	4,307 	3,949 	3,253 	3,018 	14,526 	2,749 	1,214 	4,571 	3,824 	12,358 	-21% 	18%
Less: Net (Loss) Income Attributable to Noncontrolling Interests 	(3) 	5 	5 	1 	7 	4 	1 	4 	4 	13
Net Income from Continuing Operations Attributable to Merck &
Co., Inc.
4,310 	3,944 	3,248 	3,017 	14,519 	2,745 	1,213 	4,567 	3,820 	12,345 	-21% 	18%
Income (Loss) from Discontinued Operations, Net of Taxes and
Amounts Attributable to Noncontrolling Interests
- 	- 	- 	- 	- 	434 	332 	- 	(62) 	704 	* 	*
Net Income Attributable to Merck & Co., Inc. 	4,310	$ 	3,944	$ 	3,248	$ 	3,017	$ 	14,519	$ 	3,179	$ 	1,545	$ 	4,567	$ 	3,758	$ 	13,049	$ 	-20% 	11%
Basic Earnings (Loss) per Common Share Attributable to Merck
& Co., Inc. Common Shareholders:
Income from Continuing Operations 	1.70	$ 	1.56	$ 	1.28	$ 	1.19	$ 	5.73	$ 	1.08	$ 	0.48	$ 	1.81	$ 	1.51	$ 	4.88	$ 	-21% 	17%
Income (Loss) from Discontinued Operations 	- 	- 	- 	- 	- 	0.17 	0.13 	- 	(0.02) 	0.28 	* 	*
Net Income 	1.70	$ 	1.56	$ 	1.28	$ 	1.19	$ 	5.73	$ 	1.26	$ 	0.61	$ 	1.81	$ 	1.49	$ 	5.16	$ 	-20% 	11%
Earnings (Loss) per Common Share Assuming Dilution
Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations 	1.70	$ 	1.55	$ 	1.28	$ 	1.18	$ 	5.71	$ 	1.08	$ 	0.48	$ 	1.80	$ 	1.51	$ 	4.86	$ 	-22% 	17%
Income (Loss) from Discontinued Operations 	- 	- 	- 	- 	- 	0.17 	0.13 	- 	(0.02) 	0.28 	* 	*
Net Income 	1.70	$ 	1.55	$ 	1.28	$ 	1.18	$ 	5.71	$ 	1.25	$ 	0.61	$ 	1.80	$ 	1.48	$ 	5.14	$ 	-20% 	11%
Average Shares Outstanding 	2,528 	2,531 	2,533 	2,536 	2,532 	2,531 	2,533 	2,530 	2,527 	2,530
Average Shares Outstanding Assuming Dilution 	2,537 	2,540 	2,542 	2,548 	2,542 	2,541 	2,540 	2,536 	2,535 	2,538
Tax Rate from Continuing Operations 	11.4% 	12.0% 	9.2% 	14.1% 	11.7% 	8.0% 	29.3% 	13.2% 	2.2% 	11.0%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
Table 1a
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
2022
2Q 	3Q 	4Q 	Full Year	1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
2021 % Change
4Q Full
Year
2

-- 3 of 10 --

Fourth Quarter
Cost of sales 	3,881	$ 	482 	38 	520 	3,361	$
Selling, general and administrative 	2,687 	39 	20 	59 	2,628
Research and development 	3,775 	740 	740 	3,035
Restructuring costs 	49 	49 	49 	-
Other (income) expense, net 	(75) 	(69) 	80 	11 	(86)
Income from Continuing Operations Before Taxes 	3,513 	(1,192) 	(107) 	(80) 	(1,379) 	4,892
Income Tax Provision (Benefit) 	495 	(222) (3) (32) (3) (13) (3) (267) 	762
Net Income from Continuing Operations 	3,018 	(970) 	(75) 	(67) 	(1,112) 	4,130
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 3,017 	(970) 	(75) 	(67) 	(1,112) 	4,129
Earnings per Common Share Assuming Dilution from
Continuing Operations 1.18	$ 	(0.38) 	(0.03) 	(0.03) 	(0.44) 	1.62	$
Tax Rate 	14.1% 	15.6%
Full Year
Cost of sales 	17,411	$ 	2,059 	205 	2,264 	15,147	$
Selling, general and administrative 	10,042 	176 	94 	270 	9,772
Research and development 	13,548 	1,676 	30 	1,706 	11,842
Restructuring costs 	337 	337 	337 	-
Other (income) expense, net 	1,501 	(207) 	1,348 	1,141 	360
Income from Continuing Operations Before Taxes 	16,444 	(3,704) 	(666) 	(1,348) 	(5,718) 	22,162
Income Tax Provision (Benefit) 	1,918 	(809) (3) (129) (3) (294) (3) (1,232) 	3,150
Net Income from Continuing Operations 	14,526 	(2,895) 	(537) 	(1,054) 	(4,486) 	19,012
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 14,519 	(2,895) 	(537) 	(1,054) 	(4,486) 	19,005
Earnings per Common Share Assuming Dilution from
Continuing Operations 5.71	$ 	(1.14) 	(0.21) 	(0.42) 	(1.77) 	7.48	$
Tax Rate 	11.7% 	14.2%
Only the line items that are affected by non-GAAP adjustments are shown.
MERCK & CO., INC.
FOURTH QUARTER AND FULL YEAR 2022 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
GAAP Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)
(Income) Loss from
Investments in Equity
Securities
Table 2a
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and
trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for
or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration,
transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses for the fourth quarter and full year primarily reflect $780 million
and $1.7 billion, respectively, of intangible asset impairment charges largely related to nemtabrutinib, which was obtained as part of the 2020 ArQule, Inc. acquisition, and expenses for the
amortization of intangible assets, partially offset by a reduction in expenses related to changes in the estimated fair value of liabilities for contingent consideration. Amounts included in other
(income) expense, net, for the fourth quarter and full year reflect royalty income and decreases in the estimated fair value measurement of liabilities for contingent consideration related to the prior
termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring
programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
Adjustment Subtotal 	Non-GAAP
3

-- 4 of 10 --

Fourth Quarter
Cost of sales 	3,873	$ 	419 	47 	(4) 	462 	3,411	$
Selling, general and administrative 	2,830 	226 	10 	236 	2,594
Research and development 	3,068 	397 	7 	404 	2,664
Restructuring costs 	174 	174 	174 	-
Other (income) expense, net 	(333) 	(3) 	(381) 	(384) 	51
Income from Continuing Operations Before Taxes 	3,909 	(1,039) 	(238) 	381 	4 	(892) 	4,801
Income Tax Provision (Benefit) 	85 	(163) (4) (39) (4) 84 (4) (2) (4) (120) 	205
Net Income from Continuing Operations 	3,824 	(876) 	(199) 	297 	6 	(772) 	4,596
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 3,820 	(876) 	(199) 	297 	6 	(772) 	4,592
Earnings per Common Share Assuming Dilution from
Continuing Operations 1.51	$ 	(0.34) 	(0.08) 	0.12 	- 	(0.30) 	1.81	$
Tax Rate 	2.2% 	4.3%
Full Year
Cost of sales 	13,626	$ 	1,607 	160 	221 (3) 1,988 	11,638	$
Selling, general and administrative 	9,634 	322 	19 	341 	9,293
Research and development 	12,245 	479 	28 	507 	11,738
Restructuring costs 	661 	661 	661 	-
Other (income) expense, net 	(1,341) 	76 	(1,884) 	(1,808) 	467
Income from Continuing Operations Before Taxes 	13,879 	(2,484) 	(868) 	1,884 	(221) 	(1,689) 	15,568
Income Tax Provision (Benefit) 	1,521 	(446) (4) (121) (4) 415 (4) (259) (4) (411) 	1,932
Net Income from Continuing Operations 	12,358 	(2,038) 	(747) 	1,469 	38 	(1,278) 	13,636
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 12,345 	(2,038) 	(747) 	1,469 	38 	(1,278) 	13,623
Earnings per Common Share Assuming Dilution from
Continuing Operations 4.86	$ 	(0.80) 	(0.30) 	0.58 	0.01 	(0.51) 	5.37	$
Tax Rate 	11.0% 	12.4%
Only the line items that are affected by non-GAAP adjustments are shown.
MERCK & CO., INC.
FOURTH QUARTER AND FULL YEAR 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
(4) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items for the full year also includes a $207 million
net tax benefit related to the settlement of certain federal income tax matters.
In 2022, the company changed the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck’s non-GAAP results excluded expenses for upfront and milestone
payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions, to the extent the
charges were considered by the company to be significant to the results of a particular period (as well as any related adjustments recorded in a subsequent period). Beginning in 2022, Merck’s
non-GAAP results no longer exclude charges related to these items. Results for 2021 have been recast to conform to the new presentation.
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management
believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP
measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-
GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other
costs related to acquisitions and divestitures, including $169 million of transaction costs related to the acquisition of Acceleron Pharma Inc. (Acceleron) in 2021. Amounts included in research and development expenses
primarily reflect a $275 million in-process research and development (IPR&D) impairment charge related to nemtabrutinib, which was obtained as part of the 2020 ArQule, Inc. acquisition, $105 million of Acceleron
transaction costs, and expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, reflect increases in the estimated fair value measurement of liabilities for contingent consideration
and royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture. Additionally, the full year includes a loss on a forward exchange contract entered into in conjunction with the Organon spin-off.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Reflects charges for the discontinuation of COVID-19 development programs.
GAAP Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)
(Income) Loss from
Investments in Equity
Securities
Certain Other Items 	Adjustment Subtotal
The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are
excluded from the financial information provided below.
4

-- 5 of 10 --

1Q 	2Q 	3Q 	4Q 	Full Year 	1Q 	2Q 	3Q 	4Q 	Full Year 	Nom % 	Ex-Exch % 	Nom % 	Ex-Exch %
TOTAL SALES (1) $15,901 	$14,593 	$14,959 	$13,830 	$59,283 	$10,627 	$11,402 	$13,154 	$13,521 	$48,704 	2 	8 	22 	26
PHARMACEUTICAL 	14,107 	12,756 	12,963 	12,180 	52,005 	9,238 	9,980 	11,496 	12,039 	42,754 	1 	9 	22 	28
Oncology
Keytruda 	4,809 	5,252 	5,426 	5,450 	20,937 	3,899 	4,176 	4,534 	4,577 	17,186 	19 	26 	22 	27
Alliance Revenue – Lynparza (2) 266 	275 	284 	292 	1,116 	228 	248 	246 	268 	989 	9 	14 	13 	18
Alliance Revenue – Lenvima (2) 227 	231 	202 	216 	876 	130 	181 	188 	206 	704 	5 	9 	24 	28
Alliance Revenue – Reblozyl (3) 52 	33 	39 	41 	166 	17 	17 	145 	145 	* 	*
Vaccines (4)
Gardasil / Gardasil 9 	1,460 	1,674 	2,294 	1,470 	6,897 	917 	1,234 	1,993 	1,528 	5,673 	-4 	6 	22 	27
ProQuad / M-M-R II / Varivax 	470 	578 	668 	526 	2,241 	449 	516 	661 	509 	2,135 	3 	6 	5 	7
RotaTeq 	216 	173 	256 	139 	783 	158 	208 	227 	213 	807 	-35 	-31 	-3 	0
Pneumovax 23 	173 	153 	131 	145 	602 	171 	152 	277 	292 	893 	-50 	-47 	-33 	-30
Vaqta 	36 	35 	64 	39 	173 	34 	56 	48 	41 	179 	-5 	-2 	-3 	-2
Hospital Acute Care
Bridion 	395 	426 	423 	441 	1,685 	340 	387 	369 	436 	1,532 	1 	7 	10 	16
Prevymis 	94 	103 	114 	118 	428 	82 	93 	96 	100 	370 	17 	28 	16 	24
Dificid 	52 	66 	77 	67 	263 	27 	34 	54 	60 	175 	12 	12 	50 	50
Primaxin 	58 	64 	63 	54 	239 	65 	60 	70 	65 	259 	-17 	-7 	-8 	-4
Noxafil 	57 	60 	62 	58 	238 	67 	66 	64 	62 	259 	-5 	7 	-8 	-1
Invanz 	52 	46 	50 	40 	189 	57 	48 	53 	45 	202 	-10 	-2 	-7 	-1
Cancidas 	53 	42 	43 	36 	174 	57 	54 	56 	45 	212 	-19 	-10 	-18 	-14
Zerbaxa 	30 	46 	43 	49 	169 	(8) 	(1) 	(2) 	10 	(1) 	* 	* 	* 	*
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 72 	98 	88 	82 	341 	74 	74 	100 	94 	342 	-12 	-12 	- 	-
Adempas (6) 61 	63 	57 	57 	238 	55 	74 	59 	63 	252 	-10 	6 	-6 	7
Virology
Lagevrio 	3,247 	1,177 	436 	825 	5,684 	952 	952 	-13 	2 	* 	*
Isentress / Isentress HD 	158 	147 	161 	167 	633 	209 	192 	189 	178 	769 	-7 	-1 	-18 	-13
Neuroscience
Belsomra 	69 	69 	62 	59 	258 	79 	78 	81 	80 	318 	-27 	-14 	-19 	-9
Immunology
Simponi 	186 	181 	173 	166 	706 	214 	202 	203 	206 	825 	-19 	-8 	-14 	-4
Remicade 	61 	53 	49 	44 	207 	85 	75 	73 	67 	299 	-34 	-22 	-31 	-21
Diabetes (7)
Januvia 	779 	756 	717 	561 	2,813 	809 	784 	852 	878 	3,324 	-36 	-31 	-15 	-11
Janumet 	454 	476 	417 	353 	1,700 	486 	477 	487 	514 	1,964 	-31 	-25 	-13 	-7
Other Pharmaceutical (8) 520 	479 	564 	685 	2,249 	554 	512 	518 	533 	2,118 	29 	37 	6 	12
ANIMAL HEALTH 	1,482 	1,467 	1,371 	1,230 	5,550 	1,418 	1,472 	1,417 	1,261 	5,568 	-2 	6 	- 	6
Livestock 	832 	826 	829 	814 	3,300 	819 	821 	864 	791 	3,295 	3 	12 	- 	7
Companion Animals 	650 	641 	542 	416 	2,250 	599 	651 	553 	470 	2,273 	-11 	-5 	-1 	4
Other Revenues (9) 312 	370 	625 	420 	1,728 	(29) 	(50) 	241 	221 	382 	90 	-25 	* 	87
* 200% or greater
2022 	2021 	4Q 	Full Year
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $1,305 million, $1,300 million, $1,231 million and $1,012 million in the first, second, third quarter and fourth quarter of 2022, respectively, and $1,363 million, $1,330 million,
$1,417 million and $1,475 million in the first, second, third and fourth quarter of 2021, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related
to the receipt of upfront and milestone payments for out-licensed products were $114 million, $32 million, $10 million and $10 million in the first, second, third and fourth quarter of 2022, respectively, and
$56 million, $135 million and $27 million in the first, third and fourth quarter of 2021, respectively.
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties and a milestone payment.
(4) Total Vaccines sales were $2,481 million, $2,709 million, $3,552 million and $2,554 million in the first, second, third and fourth quarter of 2022, respectively, and $1,809 million, $2,293 million, $3,315
million and $2,715 million in the first, second, third and fourth quarter of 2021, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
5

-- 6 of 10 --

4Q 2022 	4Q 2021 	% Change 	4Q 2022 	4Q 2021 	% Change 	4Q 2022 	4Q 2021 	% Change
TOTAL SALES (1) $13,830 	$13,521 	2 	$6,279 	$6,259 	- 	$7,551 	$7,262 	4
PHARMACEUTICAL 	12,180 	12,039 	1 	5,871 	5,790 	1 	6,309 	6,249 	1
Oncology
Keytruda 	5,450 	4,577 	19 	3,378 	2,657 	27 	2,071 	1,920 	8
Alliance Revenue - Lynparza (2) 292 	268 	9 	157 	144 	9 	135 	123 	9
Alliance Revenue - Lenvima (2) 216 	206 	5 	154 	131 	18 	62 	75 	-18
Alliance Revenue - Reblozyl (3) 41 	17 	145 	36 	100 	6 	17 	-66
Vaccines (4)
Gardasil / Gardasil 9 	1,470 	1,528 	-4 	262 	275 	-5 	1,207 	1,253 	-4
ProQuad / M-M-R II / Varivax 	526 	509 	3 	387 	374 	4 	139 	135 	3
Pneumovax 23 	145 	292 	-50 	66 	193 	-66 	79 	99 	-20
RotaTeq 	139 	213 	-35 	82 	109 	-25 	57 	105 	-46
Vaqta 	39 	41 	-5 	23 	20 	14 	16 	21 	-24
Hospital Acute Care
Bridion 	441 	436 	1 	257 	218 	18 	183 	218 	-16
Prevymis 	118 	100 	17 	52 	42 	25 	65 	58 	12
Dificid 	67 	60 	12 	57 	57 	-1 	10 	3 	*
Noxafil 	58 	62 	-5 	13 	11 	11 	46 	50 	-9
Primaxin 	54 	65 	-17 	1 	1 	-53 	53 	64 	-16
Zerbaxa 	49 	10 	* 	25 	9 	169 	24 	1 	*
Invanz 	40 	45 	-10 	(3) 	-86 	41 	48 	-15
Cancidas 	36 	45 	-19 	1 	* 	35 	45 	-21
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 82 	94 	-12 	85 	90 	-6 	(2) 	4 	-166
Adempas (6) 57 	63 	-10 	57 	63 	-10
Virology
Lagevrio 	825 	952 	-13 	632 	-100 	825 	320 	158
Isentress / Isentress HD 	167 	178 	-7 	78 	72 	7 	89 	106 	-16
Neuroscience
Belsomra 	59 	80 	-27 	19 	22 	-12 	39 	58 	-32
Immunology
Simponi 	166 	206 	-19 	166 	206 	-19
Remicade 	44 	67 	-34 	44 	67 	-34
Diabetes (7)
Januvia 	561 	878 	-36 	290 	407 	-29 	271 	472 	-43
Janumet 	353 	514 	-31 	97 	123 	-21 	255 	391 	-35
Other Pharmaceutical (8) 685 	533 	29 	351 	206 	70 	336 	327 	3
ANIMAL HEALTH 	1,230 	1,261 	-2 	396 	395 	- 	834 	866 	-4
Livestock 	814 	791 	3 	188 	158 	19 	626 	633 	-1
Companion Animals 	416 	470 	-11 	208 	237 	-12 	208 	233 	-10
Other Revenues (9) 420 	221 	90 	12 	74 	-84 	408 	147 	178
* 200% or greater
Sum of U.S. plus international may not equal global due to rounding.
Table 3a
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
FOURTH QUARTER 2022
(AMOUNTS IN MILLIONS)
(UNAUDITED)
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the
receipt of upfront and milestone payments for out-licensed products were $10 million in the fourth quarter of 2022 and $27 million in the fourth quarter of 2021.
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $2,554 million in the fourth quarter of 2022 and $2,715 million in the fourth quarter of 2021.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $1,012 million in the fourth quarter of 2022 and $1,475 million in the fourth quarter of 2021.
(8) Includes Pharmaceutical products not individually shown above.
6

-- 7 of 10 --

Full Year 2022 	Full Year 2021 	% Change 	Full Year 2022 	Full Year 2021 	% Change 	Full Year 2022 	Full Year 2021 	% Change
TOTAL SALES (1) $59,283 	$48,704 	22 	$27,206 	$22,425 	21 	$32,077 	$26,279 	22
PHARMACEUTICAL 	52,005 	42,754 	22 	24,989 	20,401 	22 	27,016 	22,353 	21
Oncology
Keytruda 	20,937 	17,186 	22 	12,686 	9,765 	30 	8,251 	7,421 	11
Alliance Revenue - Lynparza (2) 1,116 	989 	13 	584 	515 	13 	532 	473 	12
Alliance Revenue - Lenvima (2) 876 	704 	24 	579 	417 	39 	297 	287 	3
Alliance Revenue - Reblozyl (3) 166 	17 	* 	123 	100 	43 	17 	153
Vaccines (4)
Gardasil / Gardasil 9 	6,897 	5,673 	22 	2,065 	1,881 	10 	4,832 	3,792 	27
ProQuad / M-M-R II / Varivax 	2,241 	2,135 	5 	1,724 	1,629 	6 	518 	506 	2
RotaTeq 	783 	807 	-3 	508 	473 	8 	275 	334 	-18
Pneumovax 23 	602 	893 	-33 	346 	547 	-37 	256 	346 	-26
Vaqta 	173 	179 	-3 	95 	100 	-4 	78 	79 	-2
Hospital Acute Care
Bridion 	1,685 	1,532 	10 	922 	762 	21 	762 	770 	-1
Prevymis 	428 	370 	16 	188 	153 	23 	240 	218 	10
Dificid 	263 	175 	50 	241 	166 	45 	22 	10 	130
Primaxin 	239 	259 	-8 	1 	2 	-9 	238 	258 	-8
Noxafil 	238 	259 	-8 	51 	60 	-14 	187 	199 	-6
Invanz 	189 	202 	-7 	4 	(5) 	-171 	185 	207 	-11
Cancidas 	174 	212 	-18 	6 	4 	51 	168 	208 	-19
Zerbaxa 	169 	(1) 	* 	89 	4 	* 	79 	(5) 	*
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 341 	342 	- 	329 	312 	5 	12 	30 	-62
Adempas (6) 238 	252 	-6 	238 	252 	-6
Virology
Lagevrio 	5,684 	952 	* 	1,523 	632 	141 	4,161 	320 	*
Isentress / Isentress HD 	633 	769 	-18 	274 	294 	-7 	359 	474 	-24
Neuroscience
Belsomra 	258 	318 	-19 	79 	78 	2 	179 	241 	-26
Immunology
Simponi 	706 	825 	-14 	706 	825 	-14
Remicade 	207 	299 	-31 	207 	299 	-31
Diabetes (7)
Januvia 	2,813 	3,324 	-15 	1,248 	1,404 	-11 	1,565 	1,920 	-18
Janumet 	1,700 	1,964 	-13 	355 	367 	-3 	1,344 	1,597 	-16
Other Pharmaceutical (8) 2,249 	2,118 	6 	969 	841 	15 	1,282 	1,275 	1
ANIMAL HEALTH 	5,550 	5,568 	- 	1,822 	1,758 	4 	3,728 	3,810 	-2
Livestock 	3,300 	3,295 	- 	710 	667 	6 	2,590 	2,628 	-1
Companion Animals 	2,250 	2,273 	-1 	1,112 	1,091 	2 	1,138 	1,182 	-4
Other Revenues (9) 1,728 	382 	* 	395 	266 	48 	1,333 	116 	*
* 200% or greater
Sum of U.S. plus international may not equal global due to rounding.
Table 3b
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
FULL YEAR 2022
(AMOUNTS IN MILLIONS)
(UNAUDITED)
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues
related to the receipt of upfront and milestone payments for out-licensed products were $165 million and $218 million on a global basis for December YTD 2022 and 2021, respectively.
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties and a milestone payment.
(4) Total Vaccines sales were $11,297 million and $10,132 million on a global basis for December YTD 2022 and 2021, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $4,848 million and $5,584 million on a global basis for December YTD 2022 and 2021, respectively.
(8) Includes Pharmaceutical products not individually shown above.
7

-- 8 of 10 --

% Change
TOTAL PHARMACEUTICAL 	$14,107 	$12,756 	$12,963 	$12,180 	$52,005 	$9,238 	$9,980 	$11,496 	$12,039 	$42,754 	1 	22
United States 	6,773 	5,726 	6,620 	5,871 	24,989 	4,294 	4,647 	5,670 	5,790 	20,401 	1 	22
% Pharmaceutical Sales 	48.0% 	44.9% 	51.1% 	48.2% 	48.1% 	46.5% 	46.6% 	49.3% 	48.1% 	47.7%
Europe (1) 3,309 	2,677 	2,427 	2,494 	10,906 	2,276 	2,404 	2,445 	2,655 	9,780 	-6 	12
% Pharmaceutical Sales 	23.5% 	21.0% 	18.7% 	20.5% 	21.0% 	24.6% 	24.1% 	21.3% 	22.1% 	22.9%
China 	1,113 	1,355 	1,419 	1,216 	5,102 	688 	944 	1,278 	1,352 	4,262 	-10 	20
% Pharmaceutical Sales 	7.9% 	10.6% 	10.9% 	10.0% 	9.8% 	7.4% 	9.5% 	11.1% 	11.2% 	10.0%
Japan 	965 	1,092 	653 	832 	3,542 	607 	637 	614 	771 	2,629 	8 	35
% Pharmaceutical Sales 	6.8% 	8.6% 	5.0% 	6.8% 	6.8% 	6.6% 	6.4% 	5.3% 	6.4% 	6.1%
Asia Pacific (other than China and Japan) 	786 	854 	702 	691 	3,034 	437 	442 	450 	488 	1,817 	42 	67
% Pharmaceutical Sales 	5.6% 	6.7% 	5.4% 	5.7% 	5.8% 	4.7% 	4.4% 	3.9% 	4.1% 	4.2%
Latin America 	435 	453 	511 	472 	1,871 	353 	379 	434 	421 	1,587 	12 	18
% Pharmaceutical Sales 	3.1% 	3.6% 	3.9% 	3.9% 	3.6% 	3.8% 	3.8% 	3.8% 	3.5% 	3.7%
Eastern Europe/Middle East/Africa 	450 	339 	360 	320 	1,469 	357 	318 	362 	278 	1,315 	15 	12
% Pharmaceutical Sales 	3.2% 	2.7% 	2.8% 	2.6% 	2.8% 	3.9% 	3.2% 	3.1% 	2.3% 	3.1%
Canada 	189 	166 	166 	158 	678 	160 	157 	164 	167 	650 	-6 	4
% Pharmaceutical Sales 	1.3% 	1.3% 	1.3% 	1.3% 	1.3% 	1.7% 	1.6% 	1.4% 	1.4% 	1.5%
Other 	87 	94 	105 	126 	414 	66 	52 	79 	117 	313 	8 	32
% Pharmaceutical Sales 	0.6% 	0.6% 	0.9% 	1.0% 	0.8% 	0.8% 	0.4% 	0.8% 	0.9% 	0.8%
2022 	2021
MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
Full Year
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
2Q 	3Q 	4Q 	Full Year 	4Q	1Q 	2Q 	3Q 	4Q 	Full Year 	1Q
8

-- 9 of 10 --

OTHER (INCOME) EXPENSE, NET
4Q22 	4Q21
Full Year
2022
Full Year
2021
Interest income 	(95)	$ 	(9)	$ 	(157)	$ 	(36)	$
Interest expense 	235 	208 	962 	806
Exchange losses 	17 	95 	237 	297
Loss (income) from investments in equity securities, net (1) 59 	(403) 	1,419 	(1,940)
Net periodic defined benefit plan cost (credit) other than service cost 	(71) 	(53) 	(279) 	(212)
Other, net 	(220) 	(171) 	(681) 	(256)
Total 	(75)	$ 	(333)	$ 	1,501	$ 	(1,341)	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership
interests in investment funds are accounted for on a one quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
9

-- 10 of 10 --